Durect Corp (FRA:DC8A)
€ 0.81 -0.015 (-1.88%) Market Cap: 25.87 Mil Enterprise Value: 29.05 Mil PE Ratio: 0 PB Ratio: 22.56 GF Score: 60/100

Q1 2019 DURECT Corp Earnings Call Transcript

May 08, 2019 / 12:30PM GMT
Release Date Price: €6.56 (-4.29%)
Operator

Good day and welcome to the DURECT Corporation First Quarter 2019 Earnings and Key Opinion Leader Call. Today's conference is being recorded.

At this time, I would like to turn the conference over to Mike Arenberg, Chief Financial Officer of DURECT. Please go ahead.

Michael H. Arenberg
DURECT Corporation - CFO

Good morning. This is Mike Arenberg, Chief Financial Officer of DURECT Corporation. Welcome to our first quarter 2019 earnings conference call. During the call, in addition to financial results, we will be reporting preliminary data from our ongoing Phase IIa clinical trial of DUR-928 in patients with alcoholic hepatitis, which we refer to as AH. We are fortunate to be joined today by 3 key opinion leaders in alcoholic hepatitis, Dr. Paul Kwo from Stanford, Dr. Steven Flamm from Northwestern and Dr. Tarek Hassanein from the University of California at San Diego.

I will provide a brief review of our financial results; and then Jim Brown, our President and CEO, will provide a business update on our programs; after which we will turn

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot